Parsaclisib Is a Next-Generation PI3Kδ Inhibitor With Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy a
暂无分享,去创建一个
Kathy | Qianqian Wang | H. Koblish | M. Stubbs | Phillip C. C. Liu | T. Burn | L. Leffet | Yanlong Li | P. Waeltz | Gengjie Yang | E. Yue | A. Combs | B. Douty | B. Metcalf | S. Diamond | P. Collier | G. Hollis | S. Yeleswaram | W. Yao | R. Newton | Leslie Hall | Patricia Feldman | R. Huber | A. Roberts | D. Shuey | N. Shin | M. Soloviev | Mingming Gao | R. Collins | Kamna Katiyar | Jin Lu | Michael | He Wang | Peggy | Hansbury | Sybil O’Connor | Xin He | Yun-Long Li | Maryanne | Covington | Scherle
[1] L. Kane. Faculty Opinions recommendation of PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[2] H. Koblish,et al. INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ). , 2019, ACS medicinal chemistry letters.
[3] D. Demarini,et al. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. , 2019, Blood.
[4] J. Woodroof,et al. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status. , 2019, Human pathology.
[5] Jun Yu Li,et al. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies , 2018, Clinical Cancer Research.
[6] I. Flinn,et al. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study , 2018, American journal of hematology.
[7] M. Talpaz,et al. Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. , 2018, Blood.
[8] R. Wynn,et al. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies , 2018, PloS one.
[9] Michael R Savona,et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. , 2018, The Lancet. Oncology.
[10] Jun Yu Li,et al. INCB040093 Is a Novel PI3Kδ Inhibitor for the Treatment of B Cell Lymphoid Malignancies , 2018, The Journal of Pharmacology and Experimental Therapeutics.
[11] J. Janik,et al. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition. , 2017, Cancer research.
[12] C. Flowers,et al. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow , 2017, Expert review of anticancer therapy.
[13] V. Palombella,et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. , 2016, ACS medicinal chemistry letters.
[14] E. Elkord,et al. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting , 2016, Vaccines.
[15] L. Rassenti,et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. , 2016, Blood.
[16] Dalya R. Soond,et al. Corrigendum: Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer , 2016, Nature.
[17] A. Zelenetz,et al. Management of adverse events associated with idelalisib treatment: expert panel opinion , 2015, Leukemia & lymphoma.
[18] L. Cascione,et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.
[19] S. Plevy,et al. Innate PI3K p110δ Regulates Th1/Th17 Development and Microbiota-Dependent Colitis , 2014, The Journal of Immunology.
[20] David Dunson,et al. Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.
[21] K. Okkenhaug,et al. Blockade of Phosphatidylinositol 3-Kinase (PI3K)δ or PI3Kγ Reduces IL-17 and Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis , 2012, The Journal of Immunology.
[22] M. Gold,et al. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies , 2012, Front. Immun..
[23] R. Spang,et al. High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas , 2012, International journal of cancer.
[24] A. Hirao,et al. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. , 2021, Cell reports.
[25] M. Keating,et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. , 2011, Blood.
[26] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[27] N. Ilić,et al. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis , 2011, Proceedings of the National Academy of Sciences.
[28] S. McColl,et al. PI3Kδ drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. , 2011, Journal of autoimmunity.
[29] R. Ulrich,et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.
[30] P. Pandolfi,et al. Essential Role of the p110β Subunit of Phosphoinositide 3-OH Kinase in Male Fertility , 2010, Molecular biology of the cell.
[31] Jan Delabie,et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.
[32] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[33] Alice T. Loo,et al. PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.
[34] E. Campo,et al. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.
[35] K. Okkenhaug,et al. Cutting Edge: The Phosphoinositide 3-Kinase p110δ Is Critical for the Function of CD4+CD25+Foxp3+ Regulatory T Cells1 , 2006, The Journal of Immunology.
[36] K. Okkenhaug,et al. The p110δ Isoform of Phosphoinositide 3-Kinase Controls Clonal Expansion and Differentiation of Th Cells1 , 2006, The Journal of Immunology.
[37] E. Jaffe,et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. , 2006, Blood.
[38] D. Whyte,et al. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. , 2006, Biochemical and biophysical research communications.
[39] S. Rosenberg,et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.
[40] A. Trautmann,et al. Stable Activation of Phosphatidylinositol 3-Kinase in the T Cell Immunological Synapse Stimulates Akt Signaling to FoxO1 Nuclear Exclusion and Cell Growth Control1 , 2005, The Journal of Immunology.
[41] K. Okkenhaug,et al. Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice , 2002, Science.
[42] S. Korsmeyer,et al. bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.
[43] Dalya R. Soond,et al. PI3K p110 (cid:1) regulates T-cell cytokine production during primary and secondary immune responses in mice and humans , 2010 .
[44] I. Hers. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway. , 2007, Blood.